Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27735322 | 0.81 | RAB9A (0.58) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL10911272 | 0.81 | KMT2A (0.74) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL12489677 | 0.81 | MAPT (0.85) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL1126689 | 0.76 | MAPT (0.59) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL7902911 | 0.76 | RAB9A (0.76) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL13183698 | 0.76 | NPC1 (0.58) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL15391738 | 0.76 | NPC1 (0.42) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL12490782 | 0.75 | MAPT (1.00) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL9976069 | 0.75 | NPC1 (0.69) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL9146188 | 0.75 | NPC1 (0.69) | MAPTKMT2ARAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4472959-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148481-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2023-08-10 | — | — | WO | disclosed |
| EP-3157904-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2020-11-18 | — | — | EP | disclosed |
| US-20170121349-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2017-05-04 | — | — | US | disclosed |
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| WO-2015193506-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-12-23 | — | — | WO | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
| CN-1260781-A | Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | SMITHKLINE BEECHAM PLC (GB) | 2000-07-19 | — | — | CN | disclosed |
| EP-0975593-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | MAPT 1696/4885KMT2A 3996/4885RAB9A 729/4885 |
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | SMO, SHH, GLI1 | MAPT 4299/4885KMT2A 1286/4885RAB9A 863/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | MAPT 1696/4885KMT2A 3996/4885RAB9A 729/4885 |
| US-20170121349-A1 | Anti-Infective Compounds | FNTB, LSS, PGLS | MAPT 2813/4885KMT2A 4578/4885RAB9A 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.